Overview

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Status:
Not yet recruiting

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

This is a pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BID compared to placebo to treat hospitalized patients with non-critical COVID-19.

Phase:

Phase 3

Details

Lead Sponsor:

Azidus Brasil

Collaborators:

Farmoquimica S.A.
Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil

Treatments:

Nitazoxanide